Breast cancer four times more likely in women with strong family history
Patients using a cream containing tretinoin, a retinoid commonly used to treat acne and other conditions, appeared more likely to die than those using a placebo in a clinical trial that was halted early as a result, according to a report in the January issue of Archives of Dermatology. However, evidence does not suggest these
Full Post: Cream containing tretinoin associated with death in clinical trial, but relationship does not appear causal
Women who have a strong family history of breast cancer are over four times more likely to develop the disease than the general population, according to research published in the British Journal of Cancer.
This is the first time the risk for women who do not have a faulty BRCA gene but have one first-degree relative under 50 with breast cancer and at least one other relative with breast cancer, or three relatives of any age, has been quantified.
The lifetime risk of breast cancer in the general population is one in nine. For the group studied, this risk increased to just over one in three.
The researchers believe that a significant family history of breast cancer alone could be strong enough grounds for doctors to offer preventative treatments - such as tamoxifen, which is given to most women with breast cancer to help prevent the disease from returning.
Lead researcher, Dr Steven Narod, based at the University of Toronto in Canada, said: “Although the risk of breast cancer for this group of women - those with a family history of the disease but who don’t carry a faulty BRCA gene - is not as high as those who do carry the gene, it is still significant enough for doctors to start thinking about appropriate preventative treatments to stop women developing the disease.
“This is the first time the breast cancer risk for this group of women has been measured, and it’s significantly higher than that of the general population. It’s important to start thinking about action to prevent breast cancer in women who are at high risk of developing the disease.”
Currently in the UK, women who have a strong family history of breast cancer will be offered annual MRI scans from the age of 40 and will sometimes elect to have preventative surgery.
Previous Cancer Research UK trials have shown that tamoxifen reduces the risk of oestrogen receptor positive breast cancer - the most common kind - by between 30 to 40 per cent in women at high risk of the disease.
Professor Jack Cuzick, Cancer Research UK’s epidemiologist who leads on clinical trials to prevent breast cancer, said: “Looking at ways to prevent breast cancer is an exciting field, particularly in those who are at an increased risk of the disease. We’re also learning more about which women will respond to preventative treatments, which takes us ever closer to tailoring cancer treatment to each patient. Around 15 per cent of women with breast cancer have a family history of the disease, so around 7,000 women a year in the UK could benefit from this research.”
Dr Lesley Walker, director of cancer information at Cancer Research UK, said: “Cancer Research UK has led the way in improving our understanding of the genetics of cancer and identifying those people who would benefit most from interventions to prevent the disease before it develops or if cancer does develop to diagnose it early. These findings will help to strengthen advice to women with a strong family history of breast cancer but no evidence of a BRCA mutation.”
A baby girl about to be born in Britain will be the first to have been screened for a breast cancer causing gene. The baby’s mother, is due to give birth soon to the first British baby to have been screened to be free of a gene which can cause breast cancer. The baby’s parents
Full Post: Baby girl due soon will be minus breast cancer causing gene
Prophylactic salpingo-oophorectomy-removal of the ovaries and fallopian tubes–reduces the relative risk of breast cancer by approximately 50 percent and the risk of ovarian and fallopian tube cancer by approximately 80 percent in women who carry a mutation in the BRCA1 or BRCA2 gene, researchers report in the January 13 online issue of the Journal of
Full Post: Research confirms value of risk-reducing salpingo-oophorectomy for women with BRCA mutations
The power of the drug tamoxifen to reduce breast density is key in preventing breast cancer - according to a presentation in America by Cancer Research UK scientists. Researchers monitored the extent to which tamoxifen could reduce breast density in 7000 healthy post menopausal women who are at high risk of breast cancer in a
Full Post: How tamoxifen prevents breast cancer in some women but not others
A type of benign breast disease (BBD) known as atypical hyperplasia substantially increases a young woman’s risk of developing breast cancer, even if there is no history of breast cancer in her family, say researchers at Mayo Clinic. The investigators, who presented their findings at the Cancer Therapy & Research Center-American Association for Cancer Research
Full Post: Atypical hyperplasia increases risk of developing breast cancer
Breast cancer, the leading cause of death among women in France, is the most commonly occurring cancer in women. Sporadic breast cancer, which is non-hereditary, turns out to be the most widespread, representing 85 to 90% of all cases, but remains the least well-known. Researchers at CNRS and CEA, working with a team from H?al
Full Post: Does hormone treatment predispose patients to breast cancer?